The state of Pennsylvania currently has 540 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457
Recruiting
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania +72 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
ETHAN - ET for Male BC
NCT05501704
Recruiting
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Register for Updates
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT02945579
Recruiting
This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.
Gender:
FEMALE
Ages:
30 years and above
Trial Updated:
03/11/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Register for Updates
African Cancer Genome: GMD
NCT05754658
Recruiting
The goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry. The study is conducted by the African Caribbean Cancer Consortium (AC3) and involves the recruitment of patients from nine international AC3 research sites in the Bahamas, Barbados, Benin, Burkina Faso, Haiti, Jamaica, Kenya, Namibia, and Trinidad and Tobago, and the US. The main questions are to: molecularly characterize genomic... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/11/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Breast Cancer, Prostate Cancer
Register for Updates
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
NCT06315491
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania +1 locations
Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Register for Updates
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04841148
Recruiting
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
NCT05125016
Recruiting
This study is researching an investigational drug called REGN4336. Some participants may receive additional investigational drugs in combination with REGN4336. These additional drugs include REGN5678, cemiplimab and sarilumab. The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug) and effectiveness of REGN4336 alone, in combination with cemiplimab, or in combination with REGN5678. REGN4336, cemiplimab and REGN5678 are a type of treatment for ca... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Penn Medicine University of Pennsylvania Health System, Philadelphia, Pennsylvania +3 locations
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Collection of Circulating Biomarkers in Pancreatic Cancer
NCT05743049
Recruiting
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreas Cancer
Register for Updates
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT05758688
Recruiting
This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Lancaster General Health - Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania +1 locations
Conditions: Cervical Cancer, Uterine Cancer, Endometrial Cancer
Register for Updates
Lurbinectedin in FET-Fused Tumors
NCT05918640
Recruiting
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
03/06/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Register for Updates
Testicular Tissue Cryopreservation for Fertility Preservation
NCT02972801
Recruiting
Testicular tissue cryopreservation is an experimental procedure where a young boy's testicular tissue is retrieved and frozen. This technique is reserved for young male patients who are not yet producing mature sperm, with the ultimate goal that their tissue may be used in the future to restore fertility when experimental techniques emerge from the research pipeline.
Gender:
MALE
Ages:
All
Trial Updated:
03/05/2025
Locations: Magee-Womens Hospital, Pittsburgh, Pennsylvania
Conditions: Cancer, Autoimmune Disorders
Register for Updates